Benzinga | Dec 15, 2020 08:08AM EST

Abiomed Announces Impella Has Completed First Stage Of FDA Early Feasibility Study And FDA Has Granted 510(k) Clearance To Impella XR Sheath

Abiomed (NASDAQ:ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pump has completed the first stage in its U.S. Food and Drug Administration (FDA) early feasibility study (EFS) and the FDA has granted 510(k) clearance to the Impella XR sheath.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005395/en/